MPS World Summit

VoxCell BioInnovation proudly attended and exhibited at the Microphysiological Systems (MPS) World Summit in Brussels from June 9 to June 13, an international gathering dedicated to advancing human-relevant in vitro models.

The Summit convened more than 40 global organizations and scientific leaders to accelerate innovation in MPS technologies, including organoids, organ-on-a-chip systems, and 3D bioprinted models. These systems replicate key aspects of human tissue and organ function, offering a powerful pathway to reduce animal use in research and enhance the relevance of preclinical testing.

As exhibitors, we showcased our vascularized, 3D bioprinted cancer tissue models live on the show floor, drawing interest through hands-on demos that revealed their perfusability and realistic architecture. These conversations highlighted how VoxCell’s models go beyond traditional 3D culture systems, offering drug developers a more predictive and scalable approach for screening and discovery.

From one-on-one discussions to cross-sector panels, we were thrilled to be part of a global community pushing the boundaries of biomedical innovation through ethical, human-centric science.

About the MPS World Summit

The Microphysiological Systems World Summit is an annual event uniting scientists, engineers, regulators, and innovators working at the forefront of human-relevant model development. It fosters global collaboration to advance MPS technologies, which hold tremendous promise for accelerating drug discovery, improving patient outcomes, and reducing reliance on animal testing. The Summit serves as a key platform for harmonization, education, and innovation in complex in vitro systems.

About VoxCell BioInnovation

VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.

Want to learn more or collaborate?

Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.